Oramed COO granted 95,889 RSUs

Hexter Joshua reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Hexter Joshua reported acquisition or exercise transactions in this Form 4 filing.

ORAMED PHARMACEUTICALS INC. reported that its COO & CBO, Joshua Hexter, received a grant of 95,889 shares of Common Stock in the form of Restricted Stock Units. These RSUs will vest in eight equal quarterly installments beginning on April 1, 2026, with each RSU delivering one share upon vesting. Following this award, Hexter directly holds a total of 1,160,384 shares of the company’s common stock, reflecting a compensation-related equity grant rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 95,889 shares

Grant/Award 1 txn

Insider Hexter Joshua

Role COO & CBO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	95,889	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,160,384 shares (Direct)

Footnotes (1)

1. F1. Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Oramed (ORMP) report for Joshua Hexter?

Oramed reported that COO & CBO Joshua Hexter received 95,889 Restricted Stock Units as an equity award. These RSUs are a compensation grant, not an open-market share purchase, and increase his direct holdings to 1,160,384 shares of Oramed common stock.

How do the 95,889 RSUs granted to Oramed’s COO vest over time?

The 95,889 Restricted Stock Units granted to Oramed’s COO vest ratably in eight quarterly installments. Vesting begins on April 1, 2026, meaning one-eighth of the RSUs convert into common shares every quarter until fully vested over the defined schedule.

Is Joshua Hexter’s Oramed (ORMP) RSU award an open-market stock purchase?

No, the 95,889-share award is a grant of Restricted Stock Units, not an open-market purchase. It represents compensation awarded by Oramed that converts into common shares over time, subject to the quarterly vesting schedule starting April 1, 2026.

How many Oramed shares does COO Joshua Hexter hold after this Form 4 filing?

After the reported RSU grant, COO Joshua Hexter directly holds 1,160,384 shares of Oramed common stock. This total reflects his position immediately following the award and provides context for the scale of his equity stake in the company.

What does each Oramed Restricted Stock Unit (RSU) granted to Hexter represent?

Each RSU granted to Hexter represents the right to receive one share of Oramed common stock, with a par value of $0.012 per share. Shares are delivered only as the RSUs vest according to the eight-quarter schedule starting April 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 05:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hexter Joshua

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & CBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		A		95,889(1)	A	$0(1)	1,160,384	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

	/s/ Joshua Hexter	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)